CAR-NK cell therapy platform
Natural killer (NK) cells play an important role in fighting cancers and are emerging as an increasingly important cell type for therapeutic development.
NK cells are allogeneic and inherently target solid tumors and metastases
Edited (iPSC)-derived CAR-NK cell therapies are a compelling platform for solid tumor-targeting cell therapy development
We have developed robust differentiation and expansion protocols to derive NKs from iPSCs
Using induced pluripotent stem cells (iPSCs), we are able to differentiate and armor genome-edited CAR-NK cells to address the challenges of treating solid tumors, such as targeting, trafficking, proliferation, and overcoming the immunosuppressive tumor microenvironment.
CB-020 is the lead program from our CAR-NK platform and is in preclinical development.